Becton, Dickinson and Company

$198.96

+$4.02 (+2.06%)

Jan 5, 2026

Price History (1Y)

Analysis

Becton, Dickinson and Company (BDX) is a leading healthcare company operating in the Medical Instruments & Supplies industry. The company has a substantial market presence with a market capitalization of $56.79 billion, annual revenues of $21.84 billion, and a large employee base of 72,000 individuals. From a financial health perspective, BDX exhibits moderate profitability metrics, including a gross margin of 47.4%, operating margin of 17.9%, and profit margin of 7.7%. The company's returns on equity (6.5%) and assets (4.2%) are also within industry norms. However, its debt-to-equity ratio is relatively high at 78.85, indicating a significant reliance on external financing. The valuation context for BDX can be characterized by its P/E ratio of 33.44, forward P/E of 12.53, and price to book of 2.24. The company has experienced revenue growth of 8.3% year-over-year and earnings growth of 25.2%, indicating a relatively strong financial performance. Additionally, BDX pays out dividends with a payout ratio of 71.5%, resulting in a dividend yield of 215.0%.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Visit website →

Key Statistics

Market Cap
$56.79B
P/E Ratio
33.44
52-Week High
$251.99
52-Week Low
$162.29
Avg Volume
2.16M
Beta
0.26
Dividend Yield
215.00%

Company Info

Exchange
NYQ
Country
United States
Employees
72,000